Therapeutics News and Research

RSS

Researchers discover how STAT3 protein breaches antitumor mechanism prior to cancer development

A Stony Brook University-led international team of infectious disease researchers have discovered how a cellular protein, called STAT3, which is overactive in a majority of human cancers, interferes with an antitumor mechanism in cells and therefore promotes the growth of cancer.

18 Mar 2014

Antibe Therapeutics completes pre-clinical program for its lead product ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans.

17 Mar 2014

Adherent stromal cells derived from human placenta improve tendon healing, shows study

According to Dr. Scott Rodeo of New York's Hospital for Special Surgery (HSS), although the findings of a recent study should be considered preliminary, adherent stromal cells derived from human placenta appear promising as a readily available cell source to aid tendon healing and regeneration.

17 Mar 2014

Study suggests effective therapeutics for IBD may hinge on targeting GM-CSF axis

The protein GM-CSF plays a critical role in maintaining immune tolerance in the gut, with defects in the protein increasing the susceptibility to inflammatory bowel diseases (IBD), according to a new mouse study by a team of researchers from the Icahn School of Medicine at Mount Sinai.

17 Mar 2014

Study shows effect of oral fungal yeast in inhibiting thrush

Scientists at Case Western Reserve School of Medicine and University Hospitals (UH) Case Medical Center have discovered how the beneficial fungal yeast, Pichia, holds at bay a harmful fungal yeast, Candida.

14 Mar 2014

SAGE Therapeutics announces completion of $38 million Series C financing

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat specialty, critical and orphan central nervous system (CNS) disorders, today announced the successful completion of a $38 million Series C financing. OrbiMed Advisors, LLC, EcoR1 Capital Management, Foresite Capital Management and two undisclosed blue chip public investment funds joined existing investors Third Rock Ventures and ARCH Venture Partners.

13 Mar 2014

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Exosome Diagnostics today announced the initial close of its Series B financing round with the raising of $27 million. Proceeds will be used to advance development of the Company's proprietary platform technology and commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative diseases and other clinical areas.

11 Mar 2014

Regado receives Fast Track designation from FDA for REG1

Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program.

10 Mar 2014

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

BerGenBio AS, an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis (cancer spread) and a mechanism of drug-resistance.

10 Mar 2014

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg.

10 Mar 2014

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology.

10 Mar 2014

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.

6 Mar 2014

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

The University of Texas Medical Branch at Galveston, Profectus Biosciences, Tekmira Pharmaceuticals and the Vanderbilt University Medical Center have been awarded up to $26 million to advance treatments of the highly lethal hemorrhagic fever viruses Ebola and Marburg.

6 Mar 2014

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D).

5 Mar 2014

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and DNA Therapeutics, a biopharmaceutical company that is developing a new class of cancer drugs, are renewing their partnership.

5 Mar 2014

$Researchers develop silk-based surgical plates and screws to repair bone fractures$

Researchers develop silk-based surgical plates and screws to repair bone fractures

When a person suffers a broken bone, treatment calls for the surgeon to insert screws and plates to help bond the broken sections and enable the fracture to heal. These "fixation devices" are usually made of metal alloys.

5 Mar 2014

Stem cells from patients offer model, drug-discovery platform for early-onset form of Alzheimer's

Harvard stem cell scientists have successfully converted skins cells from patients with early-onset Alzheimer's into the types of neurons that are affected by the disease, making it possible for the first time to study this leading form of dementia in living human cells. This may also make it possible to develop therapies far more quickly and accurately than before.

5 Mar 2014

Neos Therapeutics completes private financing round, raises $15.5M

Neos Therapeutics, Inc. ("Neos" or "the Company"), a highly differentiated oral drug delivery company with an exciting portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has completed an oversubscribed round of private financing, raising a total of $15.5 million.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.

4 Mar 2014

Therapeutics News and Research

Researchers discover how STAT3 protein breaches antitumor mechanism prior to cancer development

Antibe Therapeutics completes pre-clinical program for its lead product ATB-346

Adherent stromal cells derived from human placenta improve tendon healing, shows study

Study suggests effective therapeutics for IBD may hinge on targeting GM-CSF axis

Study shows effect of oral fungal yeast in inhibiting thrush

SAGE Therapeutics announces completion of $38 million Series C financing

Exosome Diagnostics closes Series B financing round with the raising of $27 million

Regado receives Fast Track designation from FDA for REG1

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Researchers awarded $26M NIH grant to advance treatments for Ebola and Marburg

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Researchers develop silk-based surgical plates and screws to repair bone fractures

Stem cells from patients offer model, drug-discovery platform for early-onset form of Alzheimer's

Neos Therapeutics completes private financing round, raises $15.5M

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News